Last reviewed 2026-04-23 · How we verify

Ingenol Mebutate (Perrigo)

Ingenol mebutate is a protein kinase C (PKC) activator that induces rapid necrosis of actinic keratosis cells and promotes immune-mediated clearance of precancerous lesions.

Ingenol mebutate is a protein kinase C (PKC) activator that induces rapid necrosis of actinic keratosis cells and promotes immune-mediated clearance of precancerous lesions. Used for Actinic keratosis (field treatment on face, scalp, or trunk).

At a glance

Mechanism of action

Ingenol mebutate activates protein kinase C, leading to direct cytotoxic effects on keratinocytes and induction of an inflammatory response that recruits immune cells to eliminate abnormal cells. This dual mechanism of direct cell death and immune activation makes it effective for field treatment of actinic keratosis on sun-damaged skin.

Approved indications

• Actinic keratosis (field treatment on face, scalp, or trunk)

Common side effects

• Application site erythema
• Application site pain
• Application site edema
• Application site erosion
• Headache

Key clinical trials

• To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis (PHASE3)
• To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Ingenol Mebutate (Perrigo) CI brief — competitive landscape report
• Ingenol Mebutate (Perrigo) updates RSS · CI watch RSS
• Padagis LLC portfolio CI